Shares of Cadila Healthcare rose 3 per cent on the Bombay Stock Exchange after the company said that Zydus Cadila receives final approval from the USFDA for Aspirin and Extended-Release Dipyridamole Capsules. Following the announcement, shares of the company gained as much as 3.01 per cent to hit an intra-day high of Rs 512.90 apiece on the Bombay Stock Exchange.
Financial Advisory which means a lot to a Financial trader and we can do a best with your investments with all mandatory work skills subscribe us now and get two days Free Trial >> http://www.ripplesadvisory.com/free-trial.php
The stocks were currently trading at Rs 508.65 against the previous close price of Rs 497.90. In a similar fashion, shares of the company were trading 2.25 per cent higher at Rs 509.80 apiece on the National Stock Exchange.
Meanwhile, the broader benchmark BSE Sensex was trading at 31,707.79, up 319.40points, or 1.02 per cent, at 12:20 hours.